TG Therapeutics (TGTX)
55.99
-0.72 (1.27%)
Upcoming Events
Latest Headlines
Form 4 TG THERAPEUTICS, INC. For: Aug 06 Filed by: Charney Laurence N
August 7, 2026 5:01 PM - SEC Filing
TG Therapeutics (TGTX) PT Raised to $72 at JPMorgan
August 7, 2026 9:40 AM - StreetInsider
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026 7:01 AM - BizWire
Form 10-Q TG THERAPEUTICS, INC. For: Jun 30
August 5, 2026 5:02 PM - SEC Filing
TG Therapeutics (TGTX) PT Raised to $78 at H.C. Wainwright
August 4, 2026 6:50 AM - StreetInsider
Form 8-K TG THERAPEUTICS, INC. For: Aug 03
August 3, 2026 7:06 AM - SEC Filing
TG Therapeutics raises 2026 revenue guidance on Briumvi sales growth
August 3, 2026 7:03 AM - StreetInsider
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
August 3, 2026 7:00 AM - Globe NewsWire
Buy this biotech stock into Q2 earnings: Analyst
August 1, 2026 4:00 AM - StreetInsider
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
July 29, 2026 7:30 AM - Globe NewsWire
TG Therapeutics (TGTX) PT Raised to $86 at B.Riley
July 27, 2026 8:47 AM - StreetInsider
TG Therapeutics (TGTX) PT Raised to $75 at TD Cowen
July 20, 2026 6:32 AM - StreetInsider
TG Therapeutics (TGTX) PT Raised to $20 at BofA Securities
July 7, 2026 5:16 AM - StreetInsider
TG Therapeutics starts Phase 2 trial of Briumvi for schizophrenia
July 6, 2026 7:31 AM - StreetInsider
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
July 6, 2026 7:30 AM - Globe NewsWire
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026 8:30 AM - StreetInsider
Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Lonial Sagar
June 15, 2026 5:03 PM - SEC Filing
Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: HUME DANIEL
June 15, 2026 5:03 PM - SEC Filing
Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Hoberman Kenneth
June 15, 2026 5:02 PM - SEC Filing
Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Echelard Yann
June 15, 2026 5:01 PM - SEC Filing
Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Charney Laurence N
June 15, 2026 5:01 PM - SEC Filing
Form 8-K TG THERAPEUTICS, INC. For: Jun 11
June 12, 2026 4:33 PM - SEC Filing
TG Therapeutics reports positive phase 1 data for BRIUMVI in myasthenia gravis
June 9, 2026 7:30 AM - StreetInsider
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
June 9, 2026 7:30 AM - Globe NewsWire
Full Article List
